Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PARG | Q86W56 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7477529 | 1.00 | LMNA (0.31) | LMNAMAPTNPSR1ALDH1A1PARG | |
| SCHEMBL5237222 | 1.00 | LMNA (0.31) | LMNAMAPTNPSR1ALDH1A1PARG | |
| SCHEMBL7486844 | 0.88 | LMNA (0.40) | LMNAMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL7476209 | 0.84 | NOTUM (0.38) | LMNAMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL7475441 | 0.81 | MAPK8 (0.40) | LMNAMAPTALDH1A1 | |
| SCHEMBL7485767 | 0.76 | LMNA (0.32) | LMNAMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL7483009 | 0.76 | ALDH1A1 (0.34) | LMNAMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL7479670 | 0.75 | MEN1 (0.36) | LMNAMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL7482378 | 0.75 | ALDH1A1 (0.37) | LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL7475018 | 0.75 | KDM4E (0.32) | LMNAMAPTNPSR1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254907-B1 | PYRROLOPYRIDAZINE COMPOUND | SANKYO CO (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-6734181-B2 | GASTRIC ACID SECRETORY INHIBITION ACTIVITY, GASTRIC MUCOUS MEMBRANE PROTECTION ACTIVITY; TREATMENT OF ULCERS AND HELICOBACTER PYLORI INFECIONS | SANKYO COMPANY, LIMITED (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20040014762-A1 | Pyrrolopyridazine compounds | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| US-6670360-B2 | Antiulcer, antibacterial activity against Helicobacter pylori | SANKYO COMPANY, LIMITED (JP) | 2003-12-30 | — | — | US | disclosed |
| EP-1186607-B1 | OPTICALLY ACTIVE PYRROLOPYRIDAZINE COMPOUNDS | SANKYO CO (JP) | 2003-05-21 | — | — | EP | disclosed |
| EP-1254907-A1 | PYRROLOPYRIDAZINE COMPOUND | Sankyo Company, Limited (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-20020156079-A1 | Optically active pyrrolopyridazine derivatives | SANKYO COMPANY, LIMITED (JP) | 2002-10-24 | — | — | US | disclosed |
| EP-1186607-A1 | OPTICALLY ACTIVE PYRROLOPYRIDAZINE COMPOUNDS | Sankyo Company, Limited (JP) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156079-A1 | Optically active pyrrolopyridazine derivatives | GIPR, HRH2, PGA5 | LMNA 4793/4885MAPT 4805/4885NPSR1 2370/4885 |
| US-20040014762-A1 | Pyrrolopyridazine compounds | HRH2, ADH1C, GIPR | LMNA 4230/4885MAPT 4872/4885NPSR1 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.